Valuation: Lupin Limited

Market Cap 902B 9.61B 8.73B 8.06B 7.28B 13.74B 14.23B 96.96B 38.42B 484B 36.04B 35.28B 1,533B P/E 2027 *
20.9x
P/E 2028 * 20x
Enterprise Value 856B 9.11B 8.28B 7.65B 6.91B 13.04B 13.5B 92.01B 36.46B 459B 34.2B 33.48B 1,455B EV / Sales 2027 *
2.82x
EV / Sales 2028 * 2.57x
Free-Float
52.98%
Yield 2027 *
0.58%
Yield 2028 * 0.64%
1 day-0.54%
1 week-2.93%
Current month-2.35%
1 month+0.41%
3 months-13.16%
6 months-12.92%
Current year-7.11%
1 week 1,954
Extreme 1954
2,029.5
1 month 1,893.25
Extreme 1893.25
2,061.55
Current year 1,893.25
Extreme 1893.25
2,530
1 year 1,893.25
Extreme 1893.25
2,530
3 years 1,184
Extreme 1184
2,530
5 years 583.05
Extreme 583.05
2,530
10 years 505
Extreme 505
2,530
Manager TitleAgeSince
Chief Executive Officer 58 31/08/2013
President 41 21/10/2026
Director of Finance/CFO 61 12/08/2007
Director TitleAgeSince
Director/Board Member 52 07/10/2008
Director/Board Member 58 31/12/1996
Chairman 83 10/08/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.54%-2.93%-4.38%+63.99% 9.61B
-0.82%+1.40%+39.64%+143.17% 1,275B
-1.12%+0.16%+44.21%+88.24% 680B
-0.16%+0.43%+26.76%+113.01% 521B
+1.14%+2.04%+43.06%+72.81% 389B
-2.23%-2.89%+55.47%+41.64% 356B
+1.27%+1.72%+30.01%+63.11% 305B
+0.37%-0.23%+3.71%+38.05% 287B
-0.72%-0.63%+37.29%+71.87% 250B
-0.30%-1.03%+34.04%+124.88% 208B
Average -0.31%+0.26%+30.98%+82.08% 428B
Weighted average by Cap. -0.47%+0.75%+36.82%+97.95%

Financials

2027 *2028 *
Net sales 304B 3.23B 2.94B 2.71B 2.45B 4.63B 4.79B 32.65B 12.94B 163B 12.14B 11.88B 516B 322B 3.43B 3.12B 2.88B 2.6B 4.91B 5.08B 34.65B 13.73B 173B 12.88B 12.61B 548B
Net income 43.07B 459M 417M 385M 348M 656M 679M 4.63B 1.83B 23.11B 1.72B 1.68B 73.21B 45.25B 482M 438M 405M 365M 690M 714M 4.86B 1.93B 24.28B 1.81B 1.77B 76.92B
Net Debt -46.06B -491M -446M -412M -372M -702M -727M -4.95B -1.96B -24.72B -1.84B -1.8B -78.29B -74B -788M -716M -662M -598M -1.13B -1.17B -7.96B -3.15B -39.71B -2.96B -2.89B -126B
Projected Income Statement - Annual - Lupin Limited
Logo Lupin Limited
Lupin Limited is a leading Indian pharmaceutical group. Its products are used to treat tuberculosis, diabetes, asthma, cardiovascular diseases, infections, etc. The group's activity is organized around 2 areas: - design and production of generic and brand-name formulations; - production of active pharmaceutical ingredients. At the end of March 2022, the group had 15 production sites India (12), the United States, Mexico and Brazil. Net sales break down geographically as follows: India (39.4%), the United States (34.1%) and other (26.5%).
Employees
26,021
Date Price Change Volume
17/11/26 ₹1,961.80 -0.54% 9,149
16/11/26 ₹1,972.50 -0.38% 14,555
13/11/26 ₹1,980.00 -1.69% 12,670
12/11/26 ₹2,014.00 -0.35% 144,448
11/11/26 ₹2,021.00 +0.45% 11,403
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Lupin Limited
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
36
Last Close Price
1,972.50INR
Average target price
2,310.11INR
Spread / Average Target
+17.12%
  1. Stock Market
  2. Stocks
  3. LUPIN Stock